Amanta Healthcare, said that the company has received the Therapeutic Goods Administration (TGA) approval for its two products made at its Small Volume Parenterals facility at Kheda. (ET)
State Bank of India, ICICI Bank and Axis Bank are among the lenders that have sold their portion of the nearly Rs 3,000- crore loans of Arch Pharma to JM Financial Asset Reconstruction Company at less than half the value, said three people aware of the development. (ET)
Lupin is planning to strengthen its branded and specialty business in the US, according to reports. Report says that the company is planning to launch new products, brand acquisitions and even buyout of other specialty companies.
Expressing satisfaction on the export performance last year, Rita Teotia, Commerce Secretary, Ministry of Commerce, emphasized that the Indian pharmaceutical sector is strong and has ability to grow to a much larger global market share. “The Indian pharmaceutical industry is best placed to take this leap as India offers several advantages such as skilled manpower, large pool of scientists, favorable policy framework and global experience of the industry,” she says.
Sanofi India Ltd, a subsidiary of French pharma giant Sanofi SA, has announced the financial results for the quarter ended March 31, 2016. The company has posted a net profit of Rs. 80.6 crore for the quarter ended March 31, 2016 as compared to Rs. 64.5 crore reported in the same period a year ago.
Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Lacosamide Tablets, 50 mg, 100 mg, 150 mg and 200 mg.
Dr Lal PathLabs, an established brand is provider of diagnostic and healthcare related tests and services in India. The company through its integrated, nationwide network offer a broad range of diagnostic and related healthcare tests and services to patients and healthcare providers for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.
Government is looking at the financial viability for providing Rs 200 crore each to three new bulk drug manufacturing parks in order to create common minimum facilities, Parliament was informed. (ET)